Purpose: The Targeted Learning roadmap provides a systematic guide for generating and evaluating real-world evidence (RWE). From a regulatory perspective, RWE arises from diverse sources such as randomized controlled trials that make use of real-world data, observational studies, and other study designs. This paper illustrates a principled approach to assessing the validity and interpretability of RWE. Methods: We applied the roadmap to a published observational study of the dose-response association between ritodrine hydrochloride and pulmonary edema among women pregnant with twins in Japan. The goal was to identify barriers to causal effect estimation beyond unmeasured confounding reported by the study's authors, and to explore potential options for overcoming the barriers that robustify results. Results: Following the roadmap raised issues that led us to formulate alternative causal questions that produced more reliable, interpretable RWE. The process revealed a lack of information in the available data to identify a causal dose-response curve. However, under explicit assumptions the effect of treatment with any amount of ritodrine versus none, albeit a less ambitious parameter, can be estimated from data. Conclusion: Before RWE can be used in support of clinical and regulatory decision-making, its quality and reliability must be systematically evaluated. The TL roadmap prescribes how to carry out a thorough, transparent, and realistic assessment of RWE. We recommend this approach be a routine part of any decision-making process.
翻译:目标学习路线图为产生和评价现实世界证据提供了系统指南(RWE)。从监管的角度来看,REWE来自多种来源,例如利用真实世界数据、观察研究和其他研究设计进行随机控制试验,以利用真实世界数据、观察研究和其他研究设计。本文件说明了评估RWE有效性和可解释性的原则性方法。方法:我们将路线图应用于对日本双胞胎怀孕妇女血清和肺水肿之间的剂量反应关联的公开观测研究。从监管角度而言,目标是查明影响因果估计的障碍,而不是研究作者所报告的无法衡量的混杂因素,并探讨克服巩固成果的障碍的可能选择。结果:路线图提出问题,导致我们制定产生更可靠、可解释RWE的替代因果问题。 方法:我们将路线图应用于已公布的关于日本双胞胎孕妇血清和肺水肿之间剂量反应曲线的观测研究。然而,根据明确的假设,可以从数据中估算出任何程度的治疗效果相对于任何程度的治疗的效果,尽管其参数并不那么雄心勃勃。结论:在RWE作出例行决策之前,必须系统地评估其可靠性和临床决定的透明性。